Regeneron Pharmaceuticals Inc.REGN
Close of Friday, October 23, 2026 · Regeneron Pharmaceuticals Inc. is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$804.97
vs its Pivot
+9.4%
OnlyAlpha Score
74
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +1.1% | +4.7% | +38.4% | -0.5% | +8.0% |
Dividend: $3.70 a share over the last 12 months, a 0.46% yield at today's price.
Who runs and owns it
Run by Leonard Schleifer, George Yancopoulos (founder CEO; co-chair & CSO), one of the Forbes billionaires.
In these funds
Suppliers, customers and partners
Sells to REGN
| Alnylam | RNAi collaboration; royalties to Alnylam |
Partners and deals
| Sanofi | Dupixent/Kevzara; US profits 50/50 |
| Bayer AG | EYLEA ex-US |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get REGN in your free daily emailAfter every close: whether REGN is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track REGN free → Full Stock check
Track REGN free → Full Stock check